Cytotheryx, a preclinical cell therapy company developing cell-based treatments for liver disease, said it has secured a lead term sheet for a $60 million Series A round and lined up additional debt financing aimed at expanding its manufacturing and operational footprint.
The company said Ouroboros Family Founders Fund I, LP has provided a lead term sheet for the Series A, while QRS Investments, LLC is backing a separate debt facility intended to support facility expansion, including additional real estate, increased GMP manufacturing capacity, and broader operational scale-up.
Cytotheryx positioned the combined financing package as a catalyst to move multiple programs toward clinical development while continuing to build the manufacturing capabilities needed to produce therapeutic-grade liver cells at scale. The company’s platform focuses on generating clinically relevant, fully functional primary human hepatocytes—cells central to liver function—and deploying them across several therapeutic approaches for acute, chronic, and rare genetic liver diseases.
Cytotheryx said its technology portfolio includes a proprietary “bio-incubator” platform designed to enable scalable liver cell production, a bioartificial liver support system intended for acute liver failure, and a universal liver cell therapy concept aimed at transplantation for patients with rare genetic and chronic liver conditions. By pairing a lead equity raise with strategic debt, the company framed the financing as both a program-advancement step and an infrastructure buildout designed to support future clinical and manufacturing demands.
Cytotheryx is a Mayo Clinic spinout and its core differentiation is the scalable production of primary human hepatocytes for therapeutic use—an area where manufacturing consistency, supply, and functional cell quality can be major hurdles for the broader field of liver-directed cell therapies.
KEY QUOTE:
“Securing a lead Series A term sheet alongside complementary debt financing represents a pivotal milestone for Cytotheryx. This financing positions us to accelerate multiple programs into the clinic and underscores strong investor confidence in our cell therapy platform and its potential to meaningfully advance the treatment paradigm for liver disease.”
Dr. John Swart, Chief Executive Officer, Cytotheryx
